A comprehensive workup for AML should include a karyotype to identify the disease defining chromosomal translocations including t(8;21), t(15;17), t(16;16) and the new WHO entity AML with BCR/ABL (57); however, some fusions can be cryptic (57), and other testing is required to highlight these aberrations including Fluorescence in situ hybridization (FISH), RT-PCR, RNAseq, and other targeted fusions assays. This evidence concerns the gene BCR and acute myeloid leukemia.